Skip to main content
SK Bioscience Co.,Ltd logo

SK Bioscience Co.,Ltd — Investor Relations & Filings

Ticker · 302440 ISIN · KR7302440003 KO Manufacturing
Open in API
Filings indexed 381 across all filing types
Latest filing 2026-02-20 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 302440

About SK Bioscience Co.,Ltd

https://www.skbioscience.com/

SK Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines and biological products. Spun off from SK Chemicals in 2018, the company develops its own pipeline of vaccines, including cell-culture-based influenza vaccines and a COVID-19 vaccine, utilizing its established R&D and production platforms. In addition to its proprietary products, SK Bioscience provides global Contract Development and Manufacturing Organization (CDMO) services, offering end-to-end support from process development to large-scale commercial manufacturing for international partners. The company is dedicated to promoting public health by providing innovative preventative solutions to address global health challenges.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted by SK Bioscience to the Financial Supervisory Service/Korea Exchange. It details the board's resolution to grant stock options to specific executives, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding equity-based compensation and capital structure changes falls under the category of share-related regulatory filings, specifically classified as a share issue/capital change announcement.
2026-02-20 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for SK Bioscience. It contains the meeting agenda, details on voting procedures (including electronic voting), and extensive management information such as board activity reports, remuneration, and business outlook (Management Discussion and Analysis). This type of document is a standard proxy statement/information circular provided to shareholders prior to an Annual General Meeting (AGM). In the context of the provided filing categories, this aligns with 'Proxy Solicitation & Information Statement' (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2026-02-20 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy/Voting Rights) for SK Bioscience. It contains information regarding the upcoming Annual General Meeting (AGM), including the agenda, voting procedures (electronic voting/proxy), and financial statements (balance sheet, income statement, etc.) as part of the management's reference materials for shareholders. In the context of Korean regulatory filings (DART), this is a standard 'Proxy Solicitation' document provided to shareholders to request their votes for the AGM.
2026-02-20 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for SK Bioscience. It outlines the agenda items for the upcoming Annual General Meeting, including financial statement approval, board member appointments, and changes to the articles of incorporation. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting details and agenda items for voting. Therefore, it is classified as a Proxy Solicitation & Information Statement (PSI).
2026-02-20 Korean
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure regarding payment methods, payment periods, and dispute resolution mechanisms under the Fair Transactions in Subcontracting Act (하도급법). It is a specific periodic disclosure required by Korean regulatory authorities for companies to report their subcontracting payment practices. Since it does not fit into the specific categories like 10-K, IR, or ER, and is a formal regulatory filing, it is best classified as a Regulatory Filing (RNS).
2026-02-13 Korean
투자판단관련주요경영사항 (RSV 예방항체 기술도입 계약 체결)
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory disclosure from SK Bioscience regarding a 'Material Management Matter' (투자판단 관련 주요경영사항), specifically announcing a technology licensing agreement for an RSV preventative antibody. It details the counterparty, contract terms, financial implications (milestones), and board approval date. As this is a specific corporate announcement of a material business event (a contract signing) rather than a periodic report, dividend notice, or management change, it falls under the general regulatory filing category for material events.
2026-02-03 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.